Comparative Pharmacology
Head-to-head clinical analysis: CYSVIEW KIT versus ISOSULFAN BLUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYSVIEW KIT versus ISOSULFAN BLUE.
CYSVIEW KIT vs ISOSULFAN BLUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholic acid is a primary bile acid that acts as a choleretic and bile acid replacement therapy. It competitively inhibits hepatic bile acid synthesis via negative feedback on cholesterol 7α-hydroxylase (CYP7A1), reducing the production of toxic bile acid intermediates in patients with inborn errors of bile acid synthesis.
Isosulfan blue is a dye that binds to serum proteins after intradermal injection, allowing visualization of lymphatic channels and lymph nodes during sentinel lymph node biopsy. It has no known pharmacological activity beyond its use as a visual contrast agent.
Intravenous: 5 mg/kg as a single dose administered over 30 minutes.
1-2 mL (10-20 mg) of a 1% solution injected subcutaneously or intradermally around the tumor or into the tumor, typically 3-5 minutes prior to sentinel lymph node biopsy.
None Documented
None Documented
Terminal elimination half-life: 1.9-2.5 hours (mean 2.1 h) in normal renal function; prolonged in renal impairment (up to 20 h in ESRD).
Terminal elimination half-life is approximately 20-30 minutes. Clinically, the dye is rapidly cleared from the plasma, which correlates with its short duration of action as a lymphographic agent.
Renal: 90% unchanged via glomerular filtration; biliary/fecal: <5%
Primarily excreted unchanged in bile via the hepatobiliary system (approximately 90%). Renal excretion accounts for less than 10% of the administered dose.
Category C
Category C
Diagnostic Dye
Diagnostic Dye